“The sale of the PRV provides us with an important source of non-dilutive capital to help advance our pipeline of rare and ultra-rare therapies, and accelerates the availability of these potential therapies to patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
Curisium, a new healthcare technology that builds blockchain-based contracting technology for payers, providers, and life sciences companies, officially launche with the announcement that it has secured $3.5 million in seed funding.
Boston biotech resTORbio has pocketed another $40 million from a second-round financing that it hopes gives it enough cash to move its lead candidate for respiratory tract infections in elderly patients into phase 3.
Kyn is led by an Atlas entrepreneur-in-residence Mark Manfredi, who was previously chief scientific officer at Raze Therapeutics (also an Atlas-funded startup). Raze raised a $24 million Series A in 2014, but the company appears to have wound down pretty quickly. The website is no longer active, and Manfredi said Raze still has some assets and collaborations, but no longer employs anyone. Atlas’ Bruce Booth says the underlying cancer metabolism biology was too complicated to warrant further investment. Before Raze, Manfredi was VP of oncology biology at Takeda.
Most U.S. hospitals have a broad portfolio of digital technologies already in place and other innovations in early development or deployment stages, but far fewer qualify as so-called smart hospitals.
SwipeSense, a Chicago-based healthcare technology company has raised a $10.6 million in Series B2 funding led by Eclipse Ventures, with participation from Sandbox Industries and other existing technology and healthcare investors. The company plans to utilize the funding to improve its location-aware apps for healthcare platform, explore new use cases and expand its growing team.
The overall market value of in vitro diagnostics (IVD) stands at $52 billion this year, and is projected to grow at a compound annual growth rate (CAGR) of 4.2% to $69 billion in 2024. According to GlobalData, a leading data and analytics company.
The global medical sensors market is estimated to reach $15.01 billion by 2022, at a CAGR of 8.5% between 2016 and 2022. People are increasingly adopting home healthcare services owing to the rising costs of medical treatments in hospitals and medical care clinics. With this, the demand for various healthcare devices is expected to increase in the next few years.
Alexion Pharmaceuticals, Inc. (ALXN) and Halozyme Therapeutics, Inc. (HALO) announced a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. The agreement provides Alexion with the opportunity for exclusive development of up to four targets, including a next generation subcutaneous formulation of ALXN1210 (ALXN1210 SC), the company’s investigational long-acting C5 complement inhibitor, to potentially further extend the dosing interval of ALXN1210 SC to once every two weeks or once per month.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.